Health Canada Clears Aurobindo Bevacizumab Biosimilar

Aurobindo Pharma's biosimilar arm has secured approval from Health Canada's Biologics and Radiopharmaceutical Drugs Directorate for its bevacizumab biosimilar, cleared under Canada's Food and Drug Regulations. The authorization positions Aurobindo to compete directly with Roche/Genentech's Avastin in the Canadian market, adding competitive pressure to originator pricing and opening formulary access discussions for oncology programs across Canadian provinces.

Bevacizumab, a VEGF-inhibiting monoclonal antibody, is widely used across multiple oncology indications. A Health Canada-approved biosimilar entry requires manufacturers to have demonstrated analytical, clinical, and manufacturing comparability to the reference biologic under the Biologics and Radiopharmaceutical Drugs Directorate's review standards. For plant heads and QA teams at Aurobindo's biologics facilities, the approval signals that the submitted process validation data, sterility assurance controls, and GMP compliance package met Canadian regulatory expectations.

The approval was disclosed by Aurobindo Pharma through a regulatory filing originating from New Delhi. No commercial launch timeline or Canadian distribution partner was named in the filing. Provincial formulary listing, which governs reimbursed access for most Canadian oncology patients, remains a separate administrative process and will determine the practical market impact of this authorization.

Source: Aurobindo Pharma regulatory filing, as reported by Pharmaceutical Industry News, published 4 May 2026.